TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16932963
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ICS plus long-acting beta2 agonist)
Study: 11524643
Drug: Platelet glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet glycoprotein IIb/IIIa inhibitors (various studies)
Study: 11524643
Drug: Tirofiban plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban plus heparin (PRISM-PLUS study)
Study: 11524643
Drug: Integrilin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrilin therapy (PURSUIT trial)
Study: 11524643
Drug: Least harmful
Approvals — FDA: no, EMA: no, PMDA: no
Description: Least harmful treatment arm (GUSTO‐IV trial)
Study: 9458423
Drug: Linsidomine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsidomine (1 mg.h‐1 on average)
Study: 9458423
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (2.5 mg.h‐1 on average)
Study: 2693029
Drug: control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control solution (CS)
Study: 16413056
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human interleukin 11 (rhIL-11) at 50 microg/kg/day and granulocyte-macrophage colony stimulating factor (GM-CSF) at 250 microg/kg/day administered from day 11 until recovery.
Study: 16413056
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human interleukin 11 (rhIL-11) and GM-CSF as supportive care after chemotherapy.
Study: 12831635
Drug: Insulin antibodies
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin antibodies levels after severe hypoglycemia
Study: 12831635
Drug: Insulin antibodies
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin antibodies levels before severe hypoglycemia
Study: 12831635
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group insulin antibodies levels
Study: 8638169
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy at specific stages of progression of retinopathy
Study: 1630657
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg orally, t.i.d. for 7 consecutive days)
Study: 6149490
Drug: Bethanechol chloride
Normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bethanechol chloride infusion (0.05 to 0.7 mg/day)
Study: 6149490
Drug: Single‐blind saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐blind saline placebo infusions
Study: 17991659
Drug: Lycopene supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene supplementation (30 mg/d for 8 weeks)
Study: 2109432
Drug: Lactinex (culture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactinex (culture of L. acidophilus and L. bulgaricus), administered four times a day for ten days
Study: 2109432
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered four times a day for ten days
Study: 11282447
Drug: Alcoholic drinks
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic drinks (0.7 g/kg)
Study: 9215018
Drug: Intraperitoneal lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal lignocaine (50 ml containing 200 mg lignocaine and 1:500,000 adrenaline)
Study: 9215018
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (50 ml saline i.p.)
Study: 8116338
Drug: Specific cognitive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific cognitive treatment (20 pts) including direct training, compensatory strategies, and neuropsychotherapy
Study: 8116338
Drug: Specific cognitive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific cognitive treatment (20 pts)
Study: 3547053
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of elemental zinc (as 220 mg zinc sulphate), three times a day for six weeks
Study: 3547053
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of zinc a day
Study: 28401310
Drug: Daily undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily undulating periodised resistance training
Study: 23751738
Drug: Endovascular aortic
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular aortic repair (EVAR); surgical success rate 100%, perioperative mortality rate 0.8%, mean operative duration 150 min, mean blood loss 140 ml, mean hospitalization time 15.5 days, mean hospitalization cost RMB 104,800; stent graft patency 96% (120 cases), 10 deaths, 8 complications (5.6%).
Study: 23751738
Drug: Open surgery;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgery; surgical success rate 98.8%, perioperative mortality rate 2.3%, mean operative duration 230 min, mean blood loss 450 ml, mean hospitalization time 30 ± 3 days, mean hospitalization cost RMB 58,000; stent graft patency 98.8% (79 cases), 8 deaths (10%).
Study: 20734238
Drug: Legume enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legume enriched diet (1.5 servings/1,000 kcal), high fiber (21 g/1,000 kcal), low GI (GI = 38)
Study: 20734238
Drug: Healthy American
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy American diet (no legume consumption, fiber consumption = 9 g/1,000 kcal, GI = 69)
Study: 18565239
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg and 10 mg)
Study: 18565239
Drug: Tolterodine (IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (IR 2 mg bd/ER 4 mg)
Study: 15972086
Drug: Zonisamide (540
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (540 mg/day during maintenance phase)
Study: 10505585
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg for 3 to 5 days
Study: 10505585
Drug: Open-label olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label olanzapine (10-25 mg/day) for 9 weeks
Study: 7006561
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by cyclophosphamide (100 mg/kg BW in daily intravenous doses of 200 mg)
Study: 7006561
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (about 5500 rad tumour dose by telecobalt) and surgery
Study: 31819948
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with chemotherapy and/or thermotherapy
Study: 27352956
Drug: High onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High onion group (HO; n = 28) - 100 to 160 g/d of onion for 8 weeks
Study: 27352956
Drug: Low onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low onion group (LO; n = 28) - 30 to 40 g/d small onions for 8 weeks
Study: 17431101
Drug: Investigational agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational agent (growth-inhibitory drug) during the run-in period, followed by randomization to continue or discontinue therapy.
Study: 15173844
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Study: 15173844
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Study: 15173844
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC)
Study: 11224687
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Butyrates + Hydroxyurea)
Study: 9138198
Drug: Group-based behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based behavior modification intervention consisting of 5 weekly, 90-min sessions including skill training, self-monitoring, weekly feedback, and group support
Study: 2975091
Drug: Verapamil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (1 mg intracoronarily)
Study: 29430970
Drug: Pain Exposure
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Exposure Physical Therapy (maximum of five sessions)
Study: 29430970
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment conforming with the Dutch multidisciplinary guideline
Study: 23941670
Drug: 2.5 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/kg/day of amino acids (standard AA [SAA] group)
Study: 23941670
Drug: 4 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/kg/day of amino acids (high AA [HAA] group)
Study: 23941670
Drug: 2.5 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/kg/day of amino acids (SAA group)
Study: 23941670
Drug: 4 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/kg/day of amino acids (HAA group)
Study: 21923847
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (long-acting analogue; LAA)
Study: 21923847
Drug: 70% insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% insulin aspart protamine and 30% insulin aspart (biphasic insulin analogue; BIA)
Study: 21923847
Drug: Twice-daily BIA
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily BIA therapy
Study: 19808287
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and device-guided paced breathing (n=12)
Study: 19808287
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n=12)
Study: 16478629
Drug: CIAIV‐CCRT (intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIAIV‐CCRT (intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil)
Study: 16478629
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (radiation therapy alone)
Study: 16845252
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg daily
Study: 12882847
Drug: ACEI alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI alone (lisinopril/enalapril 40 mg daily or captopril 150 mg daily)
Study: 28805468
Drug: Single-pill fixed-dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-pill fixed-dose combination therapy
Study: 28805468
Drug: Two-pills combination
Normalized name: Two-Dyne Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-pills combination therapy
Study: 23851000
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) (N=30)
Study: 23851000
Drug: Child-Centered Therapy
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-Centered Therapy (CCT) (N=17)
Study: 23851000
Drug: Pre-treatment encouragement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment encouragement of bravery
Study: 21877998
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg q.d. for 4 months
Study: 19722442
Drug: Phosphoric acid
Normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphoric acid and a single-bottle dentin bonding agent (Group 2)
Study: 18086056
Drug: NASHA (Restylane
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASHA (Restylane and/or Perlane, mean dosage 69 mg)
Study: 15263832
Drug: Adrenalin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalin 0.1 mg with 10 ml 0.9% NaCl (1/100,000 dilution)
Study: 15263832
Drug: Physiological serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological serum solution
Study: 11427321
Drug: Intramuscular infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular infusion of 0.5 ml hypertonic saline (6%) into the tibialis anterior muscle
Study: 3344411
Drug: APD 30
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 30 mg
Study: 3344411
Drug: APD 45
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 45 mg
Study: 3344411
Drug: APD 60
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 60 mg
Study: 3344411
Drug: APD 90
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 90 mg
Study: 3344411
Drug: APD (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD (all doses)
Study: 22050797
Drug: Oral atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atenolol 50 mg twice daily for one day prior to surgery (Group I)
Study: 22050797
Drug: Intraoperative nitroprusside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative nitroprusside infusion (Group II)
Study: 22050797
Drug: Intraoperative esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative esmolol infusion (Group III)
Study: 18435833
Drug: Co-amoxiclav 375
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 375 mg
Study: 18435833
Drug: Antibiotics (general)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (general)
Study: 17310784
Drug: Moxifloxacin (Avelox)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (Avelox) 400 mg every 24 hours, first intravenously then orally, for a total treatment duration of 7 to 12 days (average 8.45 ± 1.53 days).
Study: 17310784
Drug: Moxifloxacin treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin treatment.
Study: 12932070
Drug: Atorvastatin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (standard doses for at least 4 months)
Study: 9120965
Drug: Intravesical morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical morphine 0.05 mg/ml
Study: 9120965
Drug: Intravesical morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical morphine 0.375 mg/ml
Study: 9120965
Drug: Intravesical morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical morphine 0.5 mg/ml
Study: 9120965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no morphine infusion)
Study: 3531226
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza virus vaccine (administered parenterally)
Study: 22389254
Drug: Ofatumumab (CD20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg)
Study: 15777291
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil (0.4 microg kg(‐1) PCA doses)
Study: 15777291
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (50% inhaled)
Study: 7730723
Drug: Minocycline 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 200 mg daily
Study: 7730723
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg daily
Study: 7730723
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg daily (after 5 months of treatment)
Study: 7730723
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg daily for 5 months)
Study: 32941
Drug: Oral androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral androgen (27 patients)
Study: 30501389
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy (3 sessions including desensitization maneuvers)
Study: 21982052
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention including oral and written explanations about cardiac rehabilitation, a follow-up telephone call, and a seminar for medical staff.
Study: 21982052
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care without additional treatment.
Study: 17760243
Drug: Lornoxicam (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (16 mg IV before surgery, 8 mg at 12h and 24h postoperatively)
Study: 17760243
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with PCA (Control Group M)
Study: 10194739
Drug: Higher methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher methadone doses
Study: 10194739
Drug: Lower methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower methadone doses
Study: 2258583
Drug: Acipimox 500
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 500 mg
Study: 6447999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-hydroxytryptophan and pyridoxine
Study: 25709055
Drug: Enhanced Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Exercise Therapy
Study: 21724950
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form II of semagacestat (140 mg)
Study: 21724950
Drug: Semagacestat (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semagacestat (140 mg) administered fed or fasting
Study: 21724950
Drug: Semagacestat (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semagacestat (140 mg) at different times of dosing (morning fasting, evening fasting)
Study: 17222829
Drug: Unopposed conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unopposed conjugated estrogen therapy (0.625 mg/d)
Study: 15703460
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 50 mg intramuscularly twice weekly combined with erythropoietin (EPO) 1,000 U three times weekly
Study: 15703460
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 1,000 U three times weekly
Study: 12127032
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine (CM) at 10 microg/kg/h intravenous infusion
Study: 12127032
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine (IM) at 30 microg/kg every 3 hours
Study: 12127032
Drug: Continuous morphine
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous morphine (CM)
Study: 12127032
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine (IM)
Study: 28854065
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg twice daily on days 1 to 5) with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Study: 28854065
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with palonosetron (0.25 mg on day 1) and dexamethasone (12 mg on day 1; 8 mg on days 2 to 4)
Study: 24606087
Drug: Low-dose rhIGF-I/rhIGFBP-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rhIGF-I/rhIGFBP-3 (30 mg/d)
Study: 24606087
Drug: High-dose rhIGF-I/rhIGFBP-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhIGF-I/rhIGFBP-3 (60 mg/d)
Study: 15628646
Drug: In-patient psychotherapeutic
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient psychotherapeutic treatment with accompanying children
Study: 15628646
Drug: In-patient psychotherapeutic
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient psychotherapeutic treatment without accompanying children
Study: 9230157
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 81 mg
Study: 9230157
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin 81 mg
Study: 9230157
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 325 mg
Study: 9230157
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin 325 mg
Study: 29050650
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard supplement)
Study: 25262253
Drug: Indapamide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (1.5 mg Slow Release (SR)/day)
Study: 19494558
Drug: Nutritional therapy,
Normalized name: nutritional therapy, ketogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy, details not specified
Study: 1672493
Drug: Intranasal cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cromolyn sodium, 1 spray in each nostril QID for 4 weeks
Study: 1672493
Drug: Oral terfenadine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terfenadine, 60 mg BID for 4 weeks
Study: 1672493
Drug: Intranasal cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cromolyn sodium